Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

Claudia Marchetti; Riccardo Tudisco; Vanda Salutari; Antonella Pietragalla; Giovanni Scambia; Anna Fagotti

doi:10.1136/ijgc-2021-002727

Article info

other Versions

You are currently viewing an earlier version of this article (January 08, 2022).
View the most recent version of this article

Clinical trial

Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

Authors

Claudia Marchetti Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Riccardo Tudisco Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Vanda Salutari Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Antonella Pietragalla Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Giovanni Scambia Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Anna Fagotti Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles

Correspondence to Anna Fagotti, Woman and Child's Health Department, Universita Cattolica del Sacro Cuore Facolta di Medicina e Chirurgia, Roma, 00168 Roma RM, Italy; annafagotti70{at}gmail.com

View Full Text

Citation

Marchetti C, Tudisco R, Salutari V, et al

Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)

International Journal of Gynecologic Cancer Published Online First: 15 June 2021. doi: 10.1136/ijgc-2021-002727

Publication history

Accepted May 27, 2021
First published June 15, 2021.

Article Versions

You are currently viewing a Previous version of this article (8 January 2022).
View the most recent version of this article

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password